Coxibs in everyday practice – whom, when, which? Discussion
Article Sidebar
Published:
Mar 31, 2018
Keywords:
coxibs, indications of use, side effects, preferences
Main Article Content
Abstract
Coxibs, as selective inhibitors of the cyclooxygenase type 2, show a strong analgesic and anti-inflammatory effect. Due to the mechanism of action, there are definitely fewer side effects on the gastrointestinal tract and generally do not require parallel use of proton pump inhibitors. In the light of the latest data, concerns about toxicity to the cardiovascular system are not confirmed. High efficacy and a small amount of side effects make them the preferred drug in patients with previous complications from the gastrointestinal tract, with the risk factors for their occurrence, but also in older people using many other drugs simultaneously.
Article Details
How to Cite
Grodzicki , T., & Tłustochowicz , W. (2018). Coxibs in everyday practice – whom, when, which?. Medycyna Faktow (J EBM), 11(1(38), 84-89. https://doi.org/10.24292/01.MF.0118.13
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Bannuru R., Schmid C., Kent D. et al.: Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann. Intern. Med. 2015; 162: 46-54.
2. Bhala N., Emberson J., Merhi A. et al.; Coxib and traditional NSAID Trialists’ (CNT) Collaboration: Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013; 382(9894): 769-779.
3. Boltem W.W.: Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs. Ann. Rheum. Dis. 2006; 65: 7-13.
4. Brænne I., Willenborg C., Tragante V. et. al.: A genomic exploration identifies mechanisms that may explain adverse cardiovascular effects of COX-2 inhibitors. Sci. Rep. 2017; 7: 10252.
5. Chan F., Lanas A., Scheiman J. et al.: Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376: 173-179.
6. Collantes E., Curtis S, Lee K. et al.; for the Etoricoxib Rheumatoid Arthritis Study Group: A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. BMC Family Practice 2002; 3: 10.
7. Combe B., Swergold G., McLay J. et al.: Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology 2009; 48: 425-432.
8. da Costa B., Reichenbach S., Keller N. et al.: Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet 2016; 387: 2093-2105.
9. Croom K., Siddiqui A.: Etoricoxib. A Review of its Use in the Symptomatic Treatment of Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis and Acute Gouty Arthritis. Drugs 2009; 69(11): 1513-1532.
10. Feng X., Tian M., Zhang W. et. al.: Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis. PLoS One 2018; 13(1): e0190798.
11. van der Heijde D., Ramiro S., Landewé R. et. al.: 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann. Rheum. Dis. 2017; 76(6): 978-991.
12. Lanas A., Boers M, Nuevo J.: Gastrointestinal events in at-risk patients starting non-steroidal anti-inflammatory drugs (NSAIDs) for rheumatic diseases: the EVIDENCE study of European routine practice. Ann. Rheum. Dis. 2015; 74: 675-681.
13. MacDonald T., Hawkey C., Ford I. et al.: Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT). Eur. Heart J. 2017; 38: 1843-1850.
14. Matsumoto A., Melian A., Mandel D. et. al.; and the Etoricoxib Rheumatoid Arthritis Study Group: A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J. Rheumatol. 2002; 29: 1623-1630.
15. Moore R., Derry S, Aldington D. et. al.: Single dose oral analgesics for acute postoperative pain in adults – an overview of Cochrane reviews. Cochrane Database Syst. Rev. 2015; (9): CD008659.
16. Nissen S., Yeomans N., Solomon D. et al.: Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N. Engl. J. Med. 2016; 375: 2519-2529.
17. Puopolo M., Boice J., Fidelholtz J. et. al.: A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with Osteoarthritis. Osteoarthritis Cartilage 2007; 15: 1348-1356.
18. Richy F., Bruyere O., Ethgen O. et al.; on behalf of the WHO Collaborating Centre for Public Health Aspects of Osteoarticular Disorders, Liège, Belgium: Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann. Rheum. Dis. 2004; 63: 759-766.
19. Ruschitzka F., Borer J., Krum H. et. al.: Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial. Eur. Heart J. 2017; 38(44): 3282-3292.
20. Scott P., Kingsley G., Smith C. et al.: Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann. Rheum. Dis. 2007; 66: 1296-1304.
21. Silverstein F., Faich G., Goldstein J. et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000; 284: 1247-1255.
22. Stam W., Jansen J., Taylor S.: Efficacy of Etoricoxib, Celecoxib, Lumiracoxib, Non-Selective NSAIDs, and Acetaminophen in Osteoarthritis: A Mixed Treatment Comparison. Open Rheumatol. J. 2012; 6: 6-20.
23. Trelle S., Reichenbach S., Wandel S. et al.: Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: c7086.
24. Zhang W., Moskowitz R., Nuki G. et al.: OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence- based, expert consensus Guidelines. Osteoarthritis Cartilage 2008; 16: 137-162.
2. Bhala N., Emberson J., Merhi A. et al.; Coxib and traditional NSAID Trialists’ (CNT) Collaboration: Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013; 382(9894): 769-779.
3. Boltem W.W.: Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs. Ann. Rheum. Dis. 2006; 65: 7-13.
4. Brænne I., Willenborg C., Tragante V. et. al.: A genomic exploration identifies mechanisms that may explain adverse cardiovascular effects of COX-2 inhibitors. Sci. Rep. 2017; 7: 10252.
5. Chan F., Lanas A., Scheiman J. et al.: Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376: 173-179.
6. Collantes E., Curtis S, Lee K. et al.; for the Etoricoxib Rheumatoid Arthritis Study Group: A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. BMC Family Practice 2002; 3: 10.
7. Combe B., Swergold G., McLay J. et al.: Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology 2009; 48: 425-432.
8. da Costa B., Reichenbach S., Keller N. et al.: Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet 2016; 387: 2093-2105.
9. Croom K., Siddiqui A.: Etoricoxib. A Review of its Use in the Symptomatic Treatment of Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis and Acute Gouty Arthritis. Drugs 2009; 69(11): 1513-1532.
10. Feng X., Tian M., Zhang W. et. al.: Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis. PLoS One 2018; 13(1): e0190798.
11. van der Heijde D., Ramiro S., Landewé R. et. al.: 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann. Rheum. Dis. 2017; 76(6): 978-991.
12. Lanas A., Boers M, Nuevo J.: Gastrointestinal events in at-risk patients starting non-steroidal anti-inflammatory drugs (NSAIDs) for rheumatic diseases: the EVIDENCE study of European routine practice. Ann. Rheum. Dis. 2015; 74: 675-681.
13. MacDonald T., Hawkey C., Ford I. et al.: Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT). Eur. Heart J. 2017; 38: 1843-1850.
14. Matsumoto A., Melian A., Mandel D. et. al.; and the Etoricoxib Rheumatoid Arthritis Study Group: A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J. Rheumatol. 2002; 29: 1623-1630.
15. Moore R., Derry S, Aldington D. et. al.: Single dose oral analgesics for acute postoperative pain in adults – an overview of Cochrane reviews. Cochrane Database Syst. Rev. 2015; (9): CD008659.
16. Nissen S., Yeomans N., Solomon D. et al.: Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N. Engl. J. Med. 2016; 375: 2519-2529.
17. Puopolo M., Boice J., Fidelholtz J. et. al.: A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with Osteoarthritis. Osteoarthritis Cartilage 2007; 15: 1348-1356.
18. Richy F., Bruyere O., Ethgen O. et al.; on behalf of the WHO Collaborating Centre for Public Health Aspects of Osteoarticular Disorders, Liège, Belgium: Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann. Rheum. Dis. 2004; 63: 759-766.
19. Ruschitzka F., Borer J., Krum H. et. al.: Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial. Eur. Heart J. 2017; 38(44): 3282-3292.
20. Scott P., Kingsley G., Smith C. et al.: Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann. Rheum. Dis. 2007; 66: 1296-1304.
21. Silverstein F., Faich G., Goldstein J. et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000; 284: 1247-1255.
22. Stam W., Jansen J., Taylor S.: Efficacy of Etoricoxib, Celecoxib, Lumiracoxib, Non-Selective NSAIDs, and Acetaminophen in Osteoarthritis: A Mixed Treatment Comparison. Open Rheumatol. J. 2012; 6: 6-20.
23. Trelle S., Reichenbach S., Wandel S. et al.: Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: c7086.
24. Zhang W., Moskowitz R., Nuki G. et al.: OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence- based, expert consensus Guidelines. Osteoarthritis Cartilage 2008; 16: 137-162.